{
    "clinical_study": {
        "@rank": "48435", 
        "acronym": "SHOview", 
        "arm_group": {
            "arm_group_label": "Highly purified menotropin (HP-hMG) treatment", 
            "description": "Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI."
        }, 
        "biospec_descr": {
            "textblock": "No biological samples"
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "Ovarian hyper stimulation syndrome (OHSS) is a potentially serious complication of ovarian\n      stimulation in IVF (In Vitro Fertilisation). The main objective of this study is to describe\n      the incidence of moderate or severe forms of OHSS in women between 18 and 36 years of age\n      treated with HP-hMG."
        }, 
        "brief_title": "Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Hyperstimulation Syndrome (OHSS)", 
        "condition_browse": {
            "mesh_term": "Ovarian Hyperstimulation Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women who present infertility of more than one year and are candidates for a first or\n             second IVF cycle with or without ICSI for whom HP-hMG is prescribed for COS.\n\n          -  Absence of infertility treatment during the last 3 months before enrolment.\n\n          -  Age: from 18 to 36 years old.\n\n          -  BMI between 18 and 30 kg / m\u00b2.\n\n          -  Presence of both ovaries accessible to puncture and absence of ovarian or uterine\n             abnormalities.\n\n          -  Male or female infertility.\n\n          -  Ovarian stimulation by HP-hMG with pituitary desensitization by a GnRH agonist or\n             antagonist.\n\n          -  Normal ovarian reserve according to physician habitual evaluation.\n\n          -  Consent to participate of the no-interventional study and signature of the patients'\n             information sheet.\n\n        Exclusion Criteria:\n\n          -  Presence of a chronic disease, cancer or endocrine disease that could potentially\n             influence the results of the stimulation or that represents a contraindication for\n             ovarian stimulation.\n\n          -  Known endometriosis grade III or IV.\n\n          -  Contraindication to the use of gonadotropins or current pregnancy diagnosed by the\n             clinician.\n\n          -  Recurrent miscarriages, known genetic disease of one of the partners or indication of\n             a preimplantation genetic diagnosis (PGD).\n\n          -  Smoking over than 10 cigarettes / day.\u00b4\n\n          -  Participation in an interventional study at the time of inclusion.\n\n          -  Known poor ovarian response in a previous cycle of stimulation (number of oocyte\n             collected \u2264 3, and / or more than 2 previous IVF/ICSI cycles and / or abnormal result\n             in ovarian reserve test (AMH < 1 ng/ml with Immunotech equipment or AMH<0.7 ng/ml\n             with DSL equipment)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "36 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS)\n        for a first or second cycle of IVF / ICSI."
            }
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703728", 
            "org_study_id": "000012"
        }, 
        "intervention": {
            "arm_group_label": "Highly purified menotropin (HP-hMG) treatment", 
            "description": "No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice", 
            "intervention_name": "Highly purified menotropin (HP- hMG) treatment", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Menotropins"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aix En Provence", 
                        "country": "France"
                    }, 
                    "name": "Cabinet Mirabeau Roy Ren\u00e9 (there may be other sites in this country)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4tel Dieu"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beaumont", 
                        "country": "France"
                    }, 
                    "name": "Clinique La Chataigneraie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France"
                    }, 
                    "name": "CHU Pellegrin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chambray les tours", 
                        "country": "France"
                    }, 
                    "name": "Clinique L\u00e9onard de Vinci"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cr\u00e9teil", 
                        "country": "France"
                    }, 
                    "name": "CHI"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dreux", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Victor Jousselin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ecully", 
                        "country": "France"
                    }, 
                    "name": "Institut Rhonalpin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France"
                    }, 
                    "name": "Cabinet M\u00e9dical Mar\u00e9chal Leclerc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Havre", 
                        "country": "France"
                    }, 
                    "name": "Groupe Hospitalier du Havre - H\u00f4pital Jacques Monod"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France"
                    }, 
                    "name": "Cabinet M\u00e9dical Lille avenue de Dunkerque"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Jeanne de Flandre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Priv\u00e9 Natecia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "CHU de Marseille -H\u00f4pital Conception"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metz", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Maternit\u00e9 de Metz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France"
                    }, 
                    "name": "CHU de Nantes"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital St Vincent de Paul"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Cabinet M\u00e9dical de Prony"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France"
                    }, 
                    "name": "CHU de Rennes"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France"
                    }, 
                    "name": "Clinique Mutualiste La Sagesse"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "SHOview Observational Study. Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.", 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France: CPP (Committee for Personal Protection)", 
                "France: CCTIRS (Advisory Committee for Data Processing in Health Research) and CNIL (Fench authority for data protection)."
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of moderate/severe OHSS", 
            "safety_issue": "Yes", 
            "time_frame": "2-12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703728"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of each form of OHSS: mild, moderate and severe", 
                "safety_issue": "Yes", 
                "time_frame": "2-13 weeks"
            }, 
            {
                "measure": "Incidence of moderate and of severe OHSS among patients treated by a GnRH agonist or antagonist desensitization protocol", 
                "safety_issue": "Yes", 
                "time_frame": "2-13 weeks"
            }, 
            {
                "measure": "OHSS clinical features description according to the Royal College of Obstetricians and Gynaecologists classification", 
                "safety_issue": "Yes", 
                "time_frame": "2-13 weeks"
            }, 
            {
                "measure": "Patients' baseline characteristics", 
                "safety_issue": "No", 
                "time_frame": "At baseline"
            }, 
            {
                "measure": "Dosage adjustment, modification of the treatment, coasting and cycle cancellation, no hCG administration and embryo transfer cancellation", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 weeks"
            }, 
            {
                "measure": "Description and duration of hospitalisation, treatments prescribed", 
                "safety_issue": "Yes", 
                "time_frame": "2-13 weeks"
            }, 
            {
                "measure": "Frequency and reasons for stimulation arrest and no embryo transfer decision", 
                "safety_issue": "Yes", 
                "time_frame": "2-4 weeks"
            }, 
            {
                "measure": "Number of oocytes retrieved, number of mature oocytes, fertilization rate, embryo quality, embryo freezing, number and quality of transferred embryos", 
                "safety_issue": "No", 
                "time_frame": "2-3 weeks"
            }, 
            {
                "measure": "Description of serious and not serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "2-13 weeks"
            }, 
            {
                "measure": "Description of patient's compliance to the prescribed treatment", 
                "safety_issue": "No", 
                "time_frame": "2-4 weeks"
            }, 
            {
                "measure": "Clinical pregnancy rate, spontaneous miscarriage and ongoing pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "4-13 weeks"
            }
        ], 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}